Myoderm Expands Its Portfolio To Include Distribution Management Services

Myoderm, a pharmaceutical supplier of comparator drugs for clinical research and clinical trials, has expanded its portfolio to include Distribution Management Services.

Reportedly, this new capability provides their clients with a solution for sourcing, managing, and distributing off-the-shelf, commercial drugs used in clinical trials.

The company said that distribution management services is cost-saving alternative to the current approach of site or patient reimbursement of commercially sourced drugs.

Reportedly, distribution management services are an extension of Myoderm’s core business of commercial drug sourcing for clinical trials. Myoderm works with over 140 pharmaceutical and biotech companies.

Mike Cohen, managing director of Myoderm, said: With Distribution Management Services, our customers will be able to diminish logistical complexities, reduce exposure to waste, greatly improve traceability and control of their drug supplies, and more easily and cost-effectively achieve the time and cost benchmarks of their trials.